These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 20472596)

  • 41. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
    Ristig MB; Crippin J; Aberg JA; Powderly WG; Lisker-Melman M; Kessels L; Tebas P
    J Infect Dis; 2002 Dec; 186(12):1844-7. PubMed ID: 12447773
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
    J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.
    Hsieh TH; Tseng TC; Liu CJ; Lai MY; Chen PJ; Hsieh HL; Chen DS; Kao JH
    Antivir Ther; 2009; 14(8):1157-63. PubMed ID: 20032545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
    Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
    Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
    Lee YH; Bae SC; Song GG
    Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy.
    Wendling D; Di Martino V; Prati C; Toussirot E; Herbein G
    Joint Bone Spine; 2009 May; 76(3):308-11. PubMed ID: 19346146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.
    Laohapand C; Arromdee E; Tanwandee T
    Hepatol Int; 2015 Apr; 9(2):202-8. PubMed ID: 25788188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
    Lee YH; Bae SC; Song GG
    Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
    Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.
    Cassano N; Mastrandrea V; Principi M; Loconsole F; De Tullio N; Di Leo A; Vena GA
    J Biol Regul Homeost Agents; 2011; 25(2):285-9. PubMed ID: 21880218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases.
    Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS
    J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents.
    Papa A; Felice C; Marzo M; Andrisani G; Armuzzi A; Covino M; Mocci G; Pugliese D; De Vitis I; Gasbarrini A; Rapaccini GL; Guidi L
    J Crohns Colitis; 2013 Mar; 7(2):113-9. PubMed ID: 22464811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
    Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
    J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study.
    Giannitti C; Lopalco G; Vitale A; Rigante D; Anelli MG; Fabbroni M; Manganelli S; Galeazzi M; Frediani B; Barone M; Lapadula G; Iannone F; Cantarini L
    Clin Exp Rheumatol; 2017; 35(1):93-97. PubMed ID: 27974094
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
    Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
    Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The long-term effects of anti-TNF-α agents on patients with chronic viral hepatitis C and B infections.
    Temel T; Cansu DÜ; Korkmaz C; Kaşifoğlu T; Özakyol A
    Int J Rheum Dis; 2015 Jan; 18(1):40-5. PubMed ID: 25195983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
    Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
    Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.